Dilated cardiomyopathy

Article written and reviewed by Dr Luca Moretti

Dilated cardiomyopathy, or DCM, is defined by left ventricular dilation and global or regional systolic dysfunction not explained exclusively by coronary artery disease or by loading conditions sufficient to produce the observed degree of abnormality. The right ventricle may be involved, but this is not required for the diagnosis. This operational definition separates the phenotype from its cause and requires investigation to continue after the geometry has been recognized.

The term cardiomyopathy should not be applied automatically to every dilated and hypokinetic ventricle. Extensive ischemic injury, severe valvular disease, uncontrolled hypertension or congenital heart disease can produce the same hemodynamic result; conversely, one of these conditions may coexist with a genetic substrate. Diagnosis therefore requires assessment of etiologic proportionality, not a simple list of exclusions.

DCM is the point of convergence of abnormalities involving the sarcomere, cytoskeleton, nuclear envelope, desmosome, metabolism, immunity and calcium homeostasis. Environmental factors may precipitate the phenotype in a genetically vulnerable carrier, while the same exposure produces different responses among individuals. The contemporary model is one of gene-environment interaction, capable of overcoming the old opposition between inherited and acquired forms.

The clinical picture includes heart failure, arrhythmias, thromboembolism and sudden death, but some patients are identified before symptoms during family screening or examinations performed for other reasons. In some genotypes, conduction disorders and ventricular arrhythmias precede dilation; in reversible forms, shock may instead be the first manifestation. The heterogeneity of presentation requires a pathway that integrates structure, electrical activity, tissue and history.

Prognosis has improved because of neurohormonal therapy, SGLT2 inhibitors, devices and advanced therapies, but it is not uniformly favorable. The same ejection fraction may be associated with very different risks according to fibrosis, genotype, right ventricular function and arrhythmias. DCM is therefore a dynamic disease: diagnosis, risk and response must be updated during follow-up rather than crystallized at the first visit.

Nosology, epidemiology and pathophysiology

Epidemiologic estimates vary with definition, ascertainment method and access to imaging. Administrative studies underestimate asymptomatic and familial forms, whereas screening programs identify mild phenotypes that have not yet reached classic criteria. Apparent prevalence is therefore the product of biology and diagnostic intensity; it is clear, however, that DCM is a major cause of heart failure and transplantation in young people.

Dilation initially increases stroke volume through the Frank-Starling mechanism, compensating for reduced force. As chamber radius increases, however, wall stress rises, energy demand increases and mechanical efficiency worsens. Eccentric remodeling thus becomes a maladaptive adaptation, driven by volume overload, apoptosis, fibrosis and extracellular matrix abnormalities.

Reduction in cardiac output and effective arterial pressure activates the sympathetic nervous system, renin-angiotensin-aldosterone system and vasopressin. These systems support perfusion and volume in the short term, but chronically increase afterload, retention, catecholamine toxicity and fibrosis. The neurohormonal response is the target of foundational therapy and explains why the benefit of medication exceeds simple modification of blood pressure.

Annular dilation and displacement of the papillary muscles prevent mitral coaptation, causing functional regurgitation. Regurgitant flow increases atrial volume and pressure, worsens congestion and promotes further dilation; analogous mechanisms affect the tricuspid valve in right-sided involvement. Secondary regurgitation is therefore part of the disease circuit and may decrease with reverse remodeling or resynchronization.

Electrical dyssynchrony, particularly with left bundle branch block, distributes work and stress inefficiently. Early-activated segments shorten while others are still relaxed, whereas late-activated segments work against an already elevated pressure. This electromechanical inefficiency can be partially reversible with resynchronization in appropriate patients, distinguishing it from irreversible myocyte loss.

Fibrosis results from cell death, inflammation and fibroblast activation. It disrupts mechanical continuity and conduction, creates reentry circuits and reduces the probability of complete recovery. The fibrotic substrate may be focal, visible as LGE, or diffuse, better represented by mapping and extracellular volume; both forms interact with genotype and disease duration.

The right ventricle may become diseased through primary involvement, overload from pulmonary hypertension or ventricular interdependence. Its failure reduces left ventricular preload, increases venous congestion and limits the use of advanced therapies. The biventricular phenotype is prognostically relevant and should not be considered merely an end-stage consequence, especially in genetic diseases involving both ventricles.

Classic DCM requires dilation, whereas nondilated left ventricular cardiomyopathy includes dysfunction or scar without increased volumes. The two categories may represent different stages or distinct expressions of the same cause, but they remain separate descriptive phenotypes. Precise classification facilitates comparison, risk assessment and screening without assuming that morphology corresponds to a single etiology.

Etiology and systematic causal investigation

Investigation begins with a detailed timeline: first symptom, infections, pregnancy, arrhythmias, substances, medications, occupational exposures and previous imaging. The duration of dysfunction modifies the plausibility of recovery and allows precipitating events to be correlated. A clinical timeline is more useful than indiscriminate collection of tests because it distinguishes cause, trigger and consequence.

A three-generation pedigree records cardiomyopathy, heart failure, transplantation, sudden death, early pacemaker implantation, skeletal myopathy and arrhythmias. Reported diagnoses such as myocardial infarction or epilepsy may conceal arrhythmic deaths, while the absence of affected relatives does not exclude de novo variants or incomplete penetrance. Familial signals guide testing and surveillance but do not replace genetic testing.

TTN truncating variants are a frequent cause, but genetically validated DCM involves genes with different mechanisms and risks, including LMNA, DSP, FLNC, BAG3, RBM20, PLN, DES, SCN5A and sarcomeric genes. An excessively broad panel increases uncertain variants without improving diagnosis. Gene-disease validity and the variant mechanism must precede any clinical conclusion.

Myocarditis and DCM are not mutually exclusive categories. An immune response may injure a genetically predisposed heart, and desmosomal variants may present with inflammatory episodes, pain and troponin elevation. Inflammatory overlap requires CMR, clinical context and sometimes biopsy; a previous common viral syndrome does not prove a persistent viral etiology.

Alcohol exerts direct toxicity through acetaldehyde, oxidative stress, mitochondrial and calcium abnormalities, but is also associated with hypertension, fibrillation and malnutrition. Cumulative dose and pattern are reconstructed in grams without assuming an absolute threshold. Susceptibility to ethanol varies and may be amplified by variants such as TTN variants, making a mixed cause possible.

Anthracyclines, HER2-targeted therapy, checkpoint inhibitors, some tyrosine kinase inhibitors and drugs of abuse cause different clinical pictures. Dose, timing, biomarkers and previous imaging help attribute injury, whereas immune-mediated myocarditis requires a different level of urgency from chronic dysfunction. Specific cardiotoxicity should be managed with oncology or addiction medicine without automatically discontinuing a life-saving therapy.

Atrial fibrillation, flutter, supraventricular tachycardias, frequent ventricular ectopy and pacing may induce or aggravate DCM. A non-extreme mean heart rate does not exclude injury from irregularity or prolonged burden. An arrhythmia-induced component is suggested by absence of scar and recovery after control, but confirmation is retrospective and does not justify waiting before treating heart failure.

Thyroid disease, pheochromocytoma, diabetes, electrolyte disorders and deficiencies of thiamine or selenium are investigated according to context. Neuromuscular and mitochondrial diseases may initially manifest in the heart, making weakness, contractures, deafness or conduction disorders valuable clues. Extracardiac red flags turn targeted testing into a high-yield diagnosis and prevent premature labeling of the case as idiopathic.

Peripartum cardiomyopathy develops toward the end of pregnancy or in the following months, but genetic DCM may be unmasked by the same stress. Previous pregnancies, remote imaging, family history and genetics help distinguish categories that may overlap. Pregnancy as a trigger has consequences for contraception, risk of recurrence and family counseling.

Manifestations, laboratory testing and electrocardiography

Exertional dyspnea, orthopnea and paroxysmal nocturnal dyspnea reflect increased left-sided pressures; edema, ascites, early satiety and hepatic pain indicate systemic congestion. Fatigue depends on output, anemia, peripheral muscle and deconditioning. Symptom burden does not follow ejection fraction linearly because pressures, adaptation and daily activity vary widely.

On examination, blood pressure and perfusion define stability more than the mere presence of edema. Jugular venous distention, hepatojugular reflux, a third heart sound, displaced apex beat and regurgitant murmurs indicate physiology, but may be absent after diuresis or in low output. Serial assessment captures changes in profile and helps distinguish adipose weight, congestion and cachexia.

Chest pain may result from concomitant coronary disease, high demand, microvascular disease, myocarditis or arrhythmia. Syncope during exertion or without prodromes raises concern for an arrhythmic cause, whereas orthostatic hypotension and medications are frequent alternatives. The semantics of the symptom, including context and prodromes, determines the pathway more than generic labels recorded in the chart.

The ECG may show sinus tachycardia, bundle branch block, atrioventricular delays, fibrillation, nonischemic Q waves, T-wave inversions or low voltages. Early atrioventricular block suggests LMNA, DES or infiltrative diseases, while frequent ectopy with a specific pattern may identify the causal focus. The electrical signal has etiologic and prognostic value even when echocardiography dominates the presentation.

Holter monitoring quantifies heart rate, arrhythmias and conduction disturbances. Twenty-four hours may be insufficient for rare symptoms, whereas prolonged telemetry or loop recorders answer different questions. The temporal burden of fibrillation or ectopy is essential for suspecting causality and assessing treatment effectiveness.

BNP and NT-proBNP reflect wall stress and support diagnosis and prognosis, but are influenced by age, rhythm, obesity and renal function. Persistent troponin elevation suggests active injury or a severe substrate without identifying its cause. Cardiac biomarkers are more useful as longitudinal components than as isolated evidence of an etiology.

Complete blood count, iron status, electrolytes, renal and hepatic function, glucose and thyroid testing identify aggravating factors and treatment safety issues. Hyponatremia, increasing azotemia and liver abnormalities may reflect advanced heart failure; interpretation must consider diuretics and volume status. Systemic laboratory testing describes how much the cardiac disease is involving the organism rather than merely separate risk factors.

Chest radiography may show cardiomegaly, congestion, effusions and alternative pulmonary diagnoses, but a normal silhouette does not exclude early DCM. Chest CT performed for other reasons may reveal dilation or coronary calcification. Extracardiac imaging contributes when interpreted in context and not used as a surrogate measure of ventricular function.

Echocardiography, magnetic resonance, genetics and biopsy

Echocardiography quantifies biplane or three-dimensional volumes, ejection fraction, strain, right ventricular function, pressures and regurgitation. Values are indexed and compared with sex and age because an apparently normal chamber may be enlarged for a small person. Echocardiographic reproducibility improves by using the same method and archived images, especially when small changes guide device decisions.

Longitudinal strain may deteriorate before ejection fraction and identify dysfunction in relatives, but depends on image quality and software. A reduced value alone does not identify the cause or define cardiomyopathy. Deformation imaging is useful when placed within a trajectory, avoiding universal thresholds applied across different platforms and populations.

Cardiac magnetic resonance provides robust measurements of volumes and function without geometric assumptions. Cine imaging, T2, native T1, extracellular volume and LGE distinguish edema, focal scar and diffuse abnormality. The tissue signature narrows the differential diagnosis and identifies risk, but its sensitivity depends on timing, technique and the ability of contrast enhancement to display relative differences.

Mid-wall septal LGE is characteristic but not exclusive to DCM and is associated with a worse prognosis. Subepicardial patterns suggest inflammatory or genetic injury, subendocardial distributions suggest ischemia, while absence of LGE does not mean normal myocardium. The geography of fibrosis should be described together with extent and context rather than reduced to present or absent.

Coronary assessment is mandatory when the probability of disease capable of explaining the phenotype is not low. Coronary CT angiography is effective in many stable patients, invasive coronary angiography is preferred in acute presentations or high pretest probability, and viability imaging answers selected questions. Coronary exclusion should be updated if symptoms or risk change, without invasively repeating tests that remain reliable.

Genetic testing is indicated when it confirms etiology, stratifies risk, informs reproduction or enables cascade testing. Pre-test counseling clarifies pathogenic, negative and uncertain results; post-test counseling links the variant to the phenotype. A VUS should not guide devices or predictive testing in relatives, but may be reassessed through segregation and new evidence.

Endomyocardial biopsy samples a minimal portion of a heterogeneous organ. Its value increases when immunohistochemistry, microscopy and molecular testing are performed in expert laboratories and when a diagnosis would immediately change treatment. Biopsy selection is crucial in unexplained shock, rapidly progressive conduction block or arrhythmias and suspected specific forms of myocarditis.

PET, scintigraphy and metabolic tests are not universal DCM investigations, but become decisive in sarcoidosis, amyloidosis or rare diseases. Selection is guided by patterns, extracardiac findings and pretest probability. An adaptive algorithm avoids both omission of treatable diseases and expensive test batteries that produce false positives and delay heart failure therapy.

Pharmacologic therapy and etiologic treatment

Therapy for reduced ejection fraction is started early, often introducing in rapid sequence an ARNI or ACE inhibitor/ARB, beta-blocker, mineralocorticoid receptor antagonist and SGLT2 inhibitor. The benefits of these classes are complementary and appear before target doses are reached. The therapeutic sequence is adapted to blood pressure, heart rate, renal function and potassium, avoiding months of incomplete monotherapy.

Sacubitril/valsartan replaces the ACE inhibitor in appropriate patients with the required washout, while evidence-based beta-blockers reduce adrenergic stimulation. Mineralocorticoid receptor antagonists require monitoring of potassium and renal function; SGLT2 inhibitors have favorable effects independent of diabetes. Medication safety depends on scheduled checks and management of intercurrent events, not on preventive therapeutic omission.

Diuretics are titrated to congestion and may be combined when resistance develops, with attention to electrolytes and renal function. An increase in creatinine during effective decongestion does not have the same meaning as deterioration with hypoperfusion. Diuretic strategy uses weight, symptoms, venous pressure and laboratory testing, avoiding both residual edema and euvolemia achieved at the cost of low output.

Ivabradine, hydralazine-nitrates, digoxin and vericiguat have selected indications according to rhythm, heart rate, ethnicity, blood pressure and recurrent events. They do not replace the foundational therapies but may address residual needs. Additional treatment should be linked to a defined clinical target because polypharmacy without hierarchy increases interactions and reduces adherence.

Elimination of the cause includes abstinence, discontinuation of drugs of abuse, arrhythmia control, correction of endocrine or nutritional disorders and shared management of cancer therapies. Discontinuing an essential medication requires balancing cardiac risk against control of the underlying disease. Etiologic treatment is carried out in parallel with heart failure therapy, not after waiting to see whether the heart recovers spontaneously.

Immunosuppression and antivirals are not empirical treatments for DCM. They are reserved for specific inflammatory diagnoses supported by histology, immunology and context, such as giant-cell or eosinophilic myocarditis, sarcoidosis or checkpoint-inhibitor toxicity. Immunologic therapy without a defined substrate may cause infection and obscure the cause without proven benefit.

Intravenous iron improves symptoms and reduces some events in patients with heart failure and deficiency according to validated criteria, whereas transfusions and erythropoiesis-stimulating agents have different indications. Thyroid disease, diabetes, obesity, sleep apnea and kidney disease are treated in a coordinated manner. Correcting comorbidities reduces demand and precipitants but does not justify diluting DCM-specific therapy.

Moderate aerobic exercise and rehabilitation improve capacity and quality of life in stable patients. The program considers arrhythmias, genotype, device, blood pressure and preferences; arrhythmogenic forms or active inflammatory disease require specific restrictions. Exercise prescription avoids both imposed sedentary behavior and unassessed return to competitive workloads.

Education, self-monitoring and early access to care reduce destabilizations. Advice on sodium and fluids is individualized because universal severe restrictions may worsen nutrition and quality of life. Daily management includes vaccinations, travel planning, recognition of congestion signs and review of NSAIDs and other medications that promote fluid retention.

Arrhythmias, thromboembolism and devices

Sudden death results from ventricular tachycardia or fibrillation, but bradyarrhythmias and electromechanical dissociation also contribute in advanced disease. Reduced ejection fraction identifies average risk, not the individual mechanism. Arrhythmic assessment integrates syncope, Holter monitoring, LGE, genotype, family history and trajectory after treatment.

An ICD for secondary prevention is indicated after cardiac arrest or hemodynamically not tolerated sustained ventricular arrhythmia not due to a reversible cause; in hemodynamically tolerated sustained ventricular tachycardia, the indication should be individualized. For primary prevention, ejection fraction, functional class, duration of therapy, life expectancy and nonarrhythmic risk define benefit; high-risk genotypes may justify earlier consideration. The benefit of the defibrillator is to terminate arrhythmias, not to prevent heart failure or cure cardiomyopathy.

Cardiac resynchronization is indicated particularly with reduced ejection fraction, symptoms and left bundle branch block with a wide QRS, but QRS morphology and duration influence response. Physiologic pacing is an emerging option in selected settings. Correction of dyssynchrony can produce marked remodeling, making it essential to distinguish a technical nonresponder from biologically refractory disease.

Atrial fibrillation worsens output and regurgitation and increases thromboembolism. Anticoagulation follows validated risk and specific conditions, whereas rate or rhythm control depends on symptoms, duration and contribution to dysfunction. Sinus rhythm may provide important benefits in arrhythmia-induced forms, but not every patient with DCM and fibrillation recovers after ablation.

Frequent ventricular ectopy may be a marker or a cause. Monomorphic morphology, high burden, absence of LGE and improvement after suppression support an induced component; multifocality and scar suggest a primary substrate. Ablation of ectopy is considered when causality and feasibility are plausible, without waiting for a universal numerical threshold.

Anticoagulation is not routinely indicated for low ejection fraction alone in sinus rhythm. It is required with atrial fibrillation according to risk, intracardiac thrombus, embolism or other indications. Ventricular thrombus is sought with contrast echocardiography or CMR when the apex is poorly visualized or probability is high, and treatment duration depends on resolution and substrate.

Device programming aims to reduce inappropriate shocks and recognize tachycardias treatable with antitachycardia pacing. Remote follow-up detects arrhythmias, congestion and technical problems, but generates data that require a response pathway. Device care includes infection, leads, MRI compatibility and replacement planning.

In patients whose function recovers after CRT or medical therapy, arrhythmic risk may decrease but does not necessarily disappear, particularly with scar or an aggressive genotype. At generator replacement, events, LGE, comorbidities and preferences are reassessed. Device de-escalation is an individual decision and not an automatic consequence of the current echocardiographic value.

Advanced heart failure, special populations and prognosis

Advanced heart failure is suggested by repeated hospitalizations, persistent symptoms, hypotension, medication intolerance, renal or hepatic dysfunction, refractory arrhythmias and markedly reduced cardiopulmonary capacity. Early referral allows assessment for mechanical support and transplantation under better conditions. Advanced-therapy timing does not necessarily wait for inotrope dependence or shock.

Right heart catheterization defines pressures, output and pulmonary vascular resistance when advanced therapy is being considered or discordance exists. Reversibility of pulmonary hypertension and right ventricular function influence candidacy and support selection. Hemodynamic phenotyping is a snapshot conditioned by volume status and medications and should be interpreted together with the trajectory.

A left ventricular assist device unloads the ventricle and restores output in selected patients as bridge or destination therapy. Right ventricular dysfunction, infection, bleeding, thrombosis and stroke remain major risks. Mechanical support requires capacity for daily management and social support in addition to anatomic and hemodynamic criteria.

Transplantation replaces the diseased heart but introduces immunosuppression, rejection, infection and graft vasculopathy. Biological age, comorbidities, malignancies, adherence and support are assessed together with cardiac severity. Transplant candidacy is a process, not a single threshold, and should begin before peripheral organs are irreversibly compromised.

During pregnancy, ACE inhibitors, ARNIs, mineralocorticoid receptor antagonists and SGLT2 inhibitors require discontinuation or substitution according to safety. Function, symptoms, arrhythmias and previous pregnancies define risk and place of delivery. Maternal management continues postpartum, a period in which volume and stress may precipitate relapse even after apparent stability.

Pediatric DCM has a different distribution of causes and a high burden of genetic, metabolic and neuromuscular disease. Growth and development change doses, interpretation of volumes and support options. Pediatric care includes nutrition, vaccinations, school and transition to adult care in addition to heart failure and arrhythmias.

In older adults, amyloidosis, ischemia, valvular disease and tachyarrhythmia become frequent alternatives, while frailty and polypharmacy modify the benefit of procedures. A label of idiopathic DCM should not prevent investigation for treatable causes. Geriatric assessment distinguishes chronological age, reserve and goals, avoiding both undertreatment and disproportionate interventions.

Contemporary prognosis depends on etiology, genotype, LGE, right ventricular function, arrhythmias and recovery. Many patients achieve years of good quality of life, whereas subgroups progress rapidly or die suddenly. Risk communication uses updatable ranges and scenarios and acknowledges uncertainty rather than presenting a cohort median as a personal prediction.

Reverse remodeling, follow-up and family

Reverse remodeling includes reduction in volumes, increase in ejection fraction, reduction in regurgitation and hemodynamic improvement. It may continue beyond the first months and does not necessarily require complete normalization to provide benefit. Structural response should be distinguished from symptom relief alone, which may result from diuresis without changing the substrate.

Favorable predictors include short duration, reversible cause, adequate blood pressure, less fibrosis and complete introduction of therapy, but none guarantees recovery. Genotypes and LGE patterns modify probability and residual risk. Predicting recovery should support realistic hope without delaying ICD implantation or advanced referral when danger is already high.

Normalization does not equal cure. TRED-HF and its follow-up show a high frequency of relapse after treatment withdrawal in patients with recovered DCM, including at a distance in time. Cardiac remission generally justifies continuation of prognosis-modifying therapy, adapted to tolerance and circumstances, and monitoring aimed at detecting early changes.

Follow-up includes clinical review, ECG, imaging, laboratory testing and rhythm monitoring at an individualized frequency. A new arrhythmia, pregnancy, infection or increase in blood pressure may precipitate relapse and brings assessment forward. Longitudinal surveillance compares original values and images because the label “recovered” may conceal a slow increase in volumes that still remain within normal ranges.

First-degree relatives undergo history, ECG and imaging; intervals depend on age, gene and history. In carriers of the familial variant, surveillance may include Holter monitoring and CMR if the gene has arrhythmic or fibrotic expression. Cascade screening enables presymptomatic prevention but must respect consent and psychological implications.

A relative who tests negative for the familial pathogenic variant can generally be released from the specific pathway unless there are doubts about causality or multiple diseases in the family. If no variant is identified in the proband, relatives remain under clinical surveillance. The meaning of a negative result therefore depends on the genetic question and not simply on the absence of a variant in the report.

Reproductive counseling discusses transmission, penetrance, variability, prenatal diagnosis and preimplantation testing without directing the choice. The probability of inheriting a variant does not equal the probability of developing severe DCM. Genetic communication separates these levels and updates interpretation when the variant is reclassified.

Optimal management connects cardiomyopathy, heart failure, imaging, electrophysiology, genetics and community medicine. Each specialist addresses part of the problem, but decisions must converge into a plan recognizable to the patient. Multidisciplinary care makes it possible to treat pump, rhythm, cause and family simultaneously, the four inseparable dimensions of DCM.

Clinical scenarios that modify the pathway

DCM presenting with shock requires circulatory support and immediate investigation for reversible causes, including fulminant myocarditis, toxicity, tachyarrhythmia and obstetric complications. Inotropes and temporary supports are used as a bridge to recovery, decision or definitive therapy. Presentation in shock compresses diagnostic time but does not justify abandoning etiologic investigation.

In suspected myocarditis, pain, troponin, CMR edema and arrhythmias must be interpreted in context because chronic DCM may show inflammatory flares. Biopsy is reserved for scenarios in which the result changes treatment, such as shock, threatening arrhythmias or suspected specific forms. The biopsy decision depends on clinical utility and not on the abstract desire for histologic confirmation.

In the peripartum setting, diagnosis requires dysfunction developing toward the end of pregnancy or in the following months without another sufficient cause. Genetic predisposition, preeclampsia and angiogenic stress may interact; future pregnancies require assessment even after recovery. Peripartum cardiomyopathy involves pharmacologic and reproductive decisions that cannot be absorbed into idiopathic DCM.

In patients with neuromuscular disease, weakness may conceal exercise intolerance and limit cardiopulmonary testing. Respiratory function, cough, conduction disorders and disease-specific medications modify management and device indications. The neuromuscular phenotype requires coordination with neurology and anesthesia and family surveillance defined by the gene.

Sarcoidosis, autoimmune diseases and infections may produce an inflammatory cardiomyopathy with disproportionate arrhythmias and conduction block. PET, CMR, extracardiac biopsy and laboratory testing are selected according to probability and the possibility of immunosuppression. Inflammatory DCM is not diagnosed from a positive autoantibody alone or from a nonspecific pattern.

Cardiomyopathy with eosinophilia, rash, asthma or a new medication requires attention to eosinophilic myocarditis and hypersensitivity. Injury may progress rapidly and biopsy may become urgent. Contextual eosinophilia is an example of an extracardiac finding that changes the invasive threshold and treatment.

In kidney disease, congestion, hyperkalemia and changes in filtration complicate initiation of prognostic medications but do not eliminate their benefit. Small initial changes may be acceptable, whereas symptomatic hypotension or progressive worsening requires reassessment of volume and drug combinations. Cardiorenal titration avoids both excessive discontinuation and unmonitored continuation.

Low blood pressure often limits titration, but asymptomatic low pressure must be distinguished from hypoperfusion. First reducing medications without prognostic benefit, correcting excessive diuresis and distributing doses may preserve the four pillars. Management of hypotension uses symptoms, perfusion and volume rather than an isolated number.

New DCM with left bundle branch block may be aggravated by dyssynchrony and respond markedly to resynchronization when criteria persist after therapy. However, the conduction abnormality may be a sign of genetic or infiltrative disease. Electrical dyssynchrony is simultaneously a therapeutic target and etiologic information.

Infections, fever, discontinuation of medications and excess sodium are common causes of decompensation, but an exacerbation may also signal recurrence of the original cause. Repeating the history on alcohol, substances, arrhythmias and new therapies is part of acute management. The precipitating factor is not assumed on the basis of previous admissions.

Cardiac rehabilitation prescribes exercise after stabilization, adapting it to arrhythmias, function and muscle diseases. Deconditioning contributes to dyspnea and correcting it improves capacity without implying myocardial recovery. Personalized rehabilitation accompanies therapy and provides a setting for education and adherence.

Noncardiac procedures require assessment of congestion, functional capacity, arrhythmias and devices, with continuation or temporary interruption of medications according to the procedure and risk. A reduced ejection fraction alone does not mandate cancellation, but active decompensation requires stabilization. Perioperative assessment translates the phenotype into an anesthetic and monitoring plan.

In patients with cancer, prognosis, cardiotoxicity and infectious risk influence devices and advanced heart failure therapy. DCM may precede, follow or be independent of cancer treatment, and chronology prevents automatic attribution. Cardio-oncology decisions balance life expectancy and benefit without reducing the patient to a single disease.

Palliative care is introduced early when symptoms and complex decisions persist, without being equivalent to abandoning active therapies. Dyspnea control, advance planning and caregiver support can coexist with LVAD therapy or transplant assessment. Symptom care remains a goal at every stage and becomes central when prognostic options are exhausted.

These scenarios show why DCM is not an algorithm defined by ejection fraction. The same ventricular geometry may require immunotherapy, ablation, cessation of a toxin, reproductive counseling or standard therapy alone. Etiologic medicine preserves the unity of the phenotype without sacrificing the differences that determine outcome and family implications.